Gemifloxacin

Gemifloxacin

SCHEMBL29408809

CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN.CS(=O)(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gyrAgyrBparCparE

The experimentally established mechanism targets of Gemifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
KDM4E B2RXH2 2/20 1.00
HSD17B10 Q99714 2/20 1.00
ABCC4 O15439 1/20 1.00
DPP4 P27487 6/20 0.93
CHRM2 P08172 1/20 0.93
DRD1 P21728 1/20 0.93
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
XBP1 P17861 1/20 0.47
NFKB1 P19838 1/20 0.47
HTT P42858 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
KCNH2 Q12809 1/20 0.44
DHFR P00374 1/20 0.43
CYP2C9 P11712 1/20 0.40
ATP6V1B2 P21281 1/20 0.40
TBXA2R P21731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gemifloxacin SCHEMBL136827 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL2421086 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL3141327 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL1237121 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL2421087 1.00 LMNA (1.00) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL5661711 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL5661708 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL3281156 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL3281159 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4
Gemifloxacin SCHEMBL5658681 0.99 LMNA (0.98) LMNAKDM4EHSD17B10ABCC4DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180649-B1 COMPACT FOLDING ARCHITECTURE FOR HEAD MOUNTED DEVICE GOOGLE LLC (US) 2022-02-23 EP claimed
US-20260041258-A1 SELF-CLOSING SECURITY DOOR ASSEMBLY FOR RETAIL DISPLAY VIRA INSIGHT LLC (US) 2026-02-12 US disclosed
US-12502012-B2 Self-closing security door assembly for retail display VIRA INSIGHT, LLC (US) 2025-12-23 US disclosed
US-12492146-B2 Solvent cement formulations OATEY CO. (US) 2025-12-09 US disclosed
US-20250185824-A1 SELF-CLOSING SECURITY DOOR ASSEMBLY FOR RETAIL DISPLAY JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE ASSISTANT 2025-06-12 US disclosed
US-20250121019-A1 METHODS AND SYSTEMS FOR MAKING OIL-LOADED POWDERS AND USE THEREOF Medisca Pharmaceutique Inc. (CA) 2025-04-17 US disclosed
EP-4499286-A1 METHODS AND SYSTEMS FOR MAKING OIL-LOADED POWDERS AND USE THEREOF MEDISCA PHARMACEUTIQUE INC. (CA) 2025-02-05 EP disclosed
US-20240326036-A1 APPARATUS FOR GAS SAMPLE COLLECTION THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2024-10-03 US disclosed
CN-113407248-B Active defense method for DDoS attack in sensing edge cloud based on flow weight control 绍兴文理学院 2024-06-21 CN disclosed
WO-2024103168-A1 METHODS AND SYSTEMS FOR MAKING OIL-LOADED POWDERS AND USE THEREOF Medisca Pharmaceutique Inc. (CA) 2024-05-23 WO disclosed
EP-4217185-A1 SOLVENT CEMENT FORMULATIONS Oatey Co. (US) 2023-08-02 EP disclosed
WO-2023102638-A2 APPARATUS FOR GAS SAMPLE COLLECTION THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-06-15 WO disclosed
US-20220234336-A1 SOFTBOOTS AND WATERPROOF/BREATHABLE MOISTURE TRANSFER COMPOSITE AND LINER FOR IN-LINE SKATES, ICE-SKATES, HOCKEY SKATES, SNOWBOARD BOOTS, ALPINE BOOTS, HIKING BOOTS AND THE LIKE SOLID WATER HOLDINGS (US) 2022-07-28 US disclosed
WO-2022140849-A1 CANNABINOID COMPOSITIONS WITH TASTE-BARRIER PROPERTIES HEXO OPERATIONS INC. (CA) 2022-07-07 WO disclosed
US-11336622-B2 Apparatus and method for deploying firewall on SDN and network using the same GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-05-17 US disclosed
US-11329988-B2 Access to a service in a network TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) 2022-05-10 US disclosed
WO-2022066684-A1 SOLVENT CEMENT FORMULATIONS OATEY CO. (US) 2022-03-31 WO disclosed
EP-3646544-B1 ACCESS TO A SERVICE IN A NETWORK ERICSSON TELEFON AB L M (SE) 2022-03-30 EP disclosed
US-20220089493-A1 Solvent Cement Formulations OATEY CO. 2022-03-24 US disclosed
EP-3180649-B1 COMPACT FOLDING ARCHITECTURE FOR HEAD MOUNTED DEVICE GOOGLE LLC (US) 2022-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041258-A1 SELF-CLOSING SECURITY DOOR ASSEMBLY FOR RETAIL DISPLAY RACK1, RNF10, CBL LMNA 722/4885KDM4E 2212/4885HSD17B10 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.